Across eight randomised trials (n=15,974) of stroke or TIA survivors, reduced-sodium salt substitution lowered stroke recurrence (RR 0.86, 95%CI 0.77-0.95) and mortality (RR 0.88, 95%CI 0.82-0.96), while Mediterranean diets raised quality of life (EQ-5D difference 10.1). Small pilots of soymilk, Trigona honey and a ketogenic diet showed functional or cognitive signals, though the ketogenic arm carried frequent adverse events. Heterogeneity precluded meta-analysis.
The salt-substitution result deserves the most weight, and it comes almost entirely from the large Phase III trials in this group, which swap a portion of sodium chloride for potassium chloride. That mirrors the logic of blood-pressure lowering, the dominant modifiable driver of recurrent stroke, and fits the broader salt-substitution literature in hypertensive and high-risk populations. The caveat is practical: potassium-enriched salt can be unsafe with advanced kidney disease or potassium-sparing medications, so survivors should clear it with their doctor. The Mediterranean quality-of-life gain is encouraging but rests on a wide confidence interval (1.8-18.4) and mostly 'some concerns' risk of bias, and it does not show reduced recurrence. The pilot findings are hypothesis-generating at best, and prone to inflated effects from small samples. The ketogenic improvements in NIHSS and mRS come with 25% keto-flu and 10% hyperlipidaemia, a poor trade for people already at vascular risk. Editorially, this is a confirmatory but valuable map of a thin evidence base: salt substitution is actionable now, while stroke-specific nutrition guidance still awaits properly powered, phase-specific trials.